Integra LifeSciences Holdings Corporation
IART
launched the NeuraGen 3D Nerve Guide Matrix— a resorbable implant for the repair of peripheral nerve discontinuities. The NeuraGen 3D is indicated for the repair of peripheral nerve discontinuities, wherein gap closure can be attained by the flexion of the extremity. However, it is important to note that the NeuraGen 3D is not recommended for patients with a known history of hypersensitivity to bovine-derived or chondroitin materials.
The NeuraGen 3D is the latest addition to Integra’s peripheral nerve repair portfolio. Compared with hollow nerve conduits alone, the NeuraGen 3D is specifically developed to generate an optimized environment that may allow a complete functional recovery after mid-gap nerve repair.
The latest launch is likely to bolster the company’s Tissue Technologies business.
More on the Benefits of NeuraGen 3D
With the addition of NeuraGen 3D to Integra’s nerve portfolio, surgeons now have access to the latest innovation in peripheral nerve repair. It is the first product to be intelligently designed and developed based on the understanding of how nerves regenerate. It is expected to help bridge the gap between hollow conduit and allograft.
The NeuraGen 3D leverages an innovative combination of Integra’s bovine type 1 collagen and the Integra Dermal Regeneration Template technology. The porous channels of NeuraGen 3D’s unique inner matrix have been pre-clinically demonstrated to help guide Schwann cell migration and direct axonal growth, which is an important goal for surgeons to treat nerve repair and restore function.
Image Source: Zacks Investment Research
The NeuraGen 3D is a huge step forward in peripheral nerve repair injury treatment. Per management, it is the company’s most innovative and advanced matrix product to reach markets in several decades. It bears the potential to make a significant contribution to patient care.
Industry Prospects
Per a report
published in MarketsandMarkets, the global nerve repair and regeneration market is expected to see a CAGR of 9.1% between 2020 and 2025. Factors such as greater incidence of nerve injuries, rising neurological disorders, a surge in the geriatric population, and increased government support for neurologic disorders are driving the market.
Given the market prospects, Integra’s latest launch for nerve repair comes at an opportune time.
Notable Developments in Tissue Technologies
In the fourth quarter of 2021, Integra’s Tissue Technologies revenues were up 0.4% year over year on a reported basis and 6.7% on an organic basis. Sales in wound reconstruction improved 3.8% year over year on an organic basis, driven by Integra Skin and SurgiMend in the company’s burn, trauma and surgical reconstruction markets.
The ACell business stabilized in the fourth quarter, with sales of $16.9 million in line with the November guidance. The ongoing recovery in customer orders led to 15% growth in private label sales from 2020.
Share Price Performance
The stock has outperformed its
industry
over the past six months. It has declined 10.4% against the industry’s 15.2% fall.
Zacks Rank and Key Picks
Currently, Integra carries a Zacks Rank #3 (Hold).
A few better-ranked stocks in the broader medical space are
Henry Schein, Inc.
HSIC
,
McKesson Corporation
MCK
and
IDEXX Laboratories, Inc.
IDXX
.
Henry Schein has an estimated long-term growth rate of 11.8%. HSIC’s earnings surpassed estimates in the trailing four quarters, the average surprise being 25.5%. It currently has a Zacks Rank #2 (Buy). You can see
the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Henry Schein has outperformed the industry over the past year. HSIC has gained 34.8% compared with the industry’s 10.9% rise over the past year.
McKesson has a long-term earnings growth rate of 11.8%. MCK’s earnings surpassed estimates in the trailing four quarters, delivering a surprise of 20.6%, on average. It presently carries a Zacks Rank #2.
McKesson has outperformed the industry over the past year. MCK has gained 59.8% in the said period compared with 10.9% growth of the industry.
IDEXX has a long-term earnings growth rate of 13%. The company’s earnings surpassed estimates in the trailing four quarters, delivering an average surprise of 18.6%. IDXX currently has a Zacks Rank #2.
IDEXX has outperformed its industry in the past year. IDXX has gained 16.8% against the industry’s 1.2% growth in the same period.
Investor Alert: Legal Marijuana Looking for big gains?
Now is the time to get in on a young industry primed to skyrocket from $13.5 billion in 2021 to an expected $70.6 billion by 2028.
After a clean sweep of 6 election referendums in 5 states, pot is now legal in 36 states plus D.C. Federal legalization is expected soon and that could kick start an even greater bonanza for investors. Zacks Investment Research has recently closed pot stocks that have shot up as high as +147.0%.
You’re invited to immediately check out Zacks’
Marijuana Moneymakers: An Investor’s Guide
. It features a timely Watch List of pot stocks and ETFs with exceptional growth potential.
Today, Download Marijuana Moneymakers FREE >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
